Stock analysis searches answered, part 5 of 43

Prestige consumer healthcare pbh latest news october 2026

This section ties “Prestige consumer healthcare pbh latest news october 2026” to Prestige Consumer Healthcare Inc. (ticker PBH), SEC Central Index Key 1295947, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in an unstated jurisdiction, formerly known as Prestige Brands Holdings, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-05-14 by Prestige Consumer Healthcare Inc. (CIK 1295947) — source document:

Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., “2026”) refers to our fiscal year ended March 31 of that year. We formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter (“OTC”) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.

Financial trend for Prestige Consumer Healthcare Inc. from annual reports, periods 2023-03-31 to 2026-03-31: net income (loss) went from -$82.31 million (2023-03-31) to $190.30 million (2026-03-31), a change of +331.2%; total assets went from $3.35 billion (2023-03-31) to $3.49 billion (2026-03-31), a change of +4.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1295947, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Prestige Consumer Healthcare Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Prestige Consumer Healthcare Inc. (CIK 1295947) filed 157 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-14, and its overall latest filing is a 8-K dated 2026-08-14. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 157 8-K or 6-K reports in Prestige Consumer Healthcare Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-06 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1295947 is on the EDGAR company page; the latest 10-K there is dated 2026-05-14 and the oldest filing in the recent index dates from 2008-11-06. Insider trades for Prestige Consumer Healthcare Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sagtec global ltd bullish and bearish analyst opinions

This section ties “Sagtec global ltd bullish and bearish analyst opinions” to SAGTEC GLOBAL Ltd (ticker SAGT), SEC Central Index Key 2029138, an EDGAR registrant classified as “Services-Prepackaged Software” and organised in Malaysia. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-29 by SAGTEC GLOBAL Ltd (CIK 2029138) — source document:

The chart below sets forth our corporate structure as of the date of this annual report: Entities A description of our principal operating subsidiaries is set forth below. On June 11, 2018, Sagtec Group was incorporated in Malaysia as a private company limited by shares. On May 27, 2019, Sagtec Group changed its name from Signage Alliance Group Sdn Bhd to Sagtec Group Sdn Bhd It commenced business on June 11, 2018 and is engaged in the provision of customizable software solutions. The solutions Sagtec Group provides include subscription services, software consultation and development services, social media management, data management and analysis services and sales of food ordering kiosks with screens.

Financial trend for SAGTEC GLOBAL Ltd from annual reports, periods 2022-12-31 to 2024-12-31: revenue went from 13,000,026 MYR (2022-12-31) to 51,999,379 MYR (2024-12-31), a change of +300.0%; net income (loss) went from 2,363,584 MYR (2022-12-31) to 7,165,510 MYR (2024-12-31), a change of +203.2%; total assets went from 21,298,628 MYR (2023-12-31) to 27,354,501 MYR (2024-12-31), a change of +28.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2029138, tags Assets, ProfitLoss, Revenue; 3 periods shown, dashes mark figures SAGTEC GLOBAL Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SAGTEC GLOBAL Ltd (CIK 2029138) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 31 8-K or 6-K reports in SAGTEC GLOBAL Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-20 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2029138 is on the EDGAR company page; the latest 20-F there is dated 2026-04-29 and the oldest filing in the recent index dates from 2024-08-16. Insider trades for SAGTEC GLOBAL Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Skillsoft corp. bullish and bearish analyst opinions

This section ties “Skillsoft corp. bullish and bearish analyst opinions” to Skillsoft Corp. (ticker SKIL), SEC Central Index Key 1774675, an EDGAR registrant classified as “Services-Prepackaged Software” and organised in DE, formerly known as Churchill Capital Corp II. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-07 by Skillsoft Corp. (CIK 1774675) — source document:

We were originally incorporated in Delaware on April 11, 2019 under the name “Hornblower Acquisition Corp.” Our name was changed to “Churchill Capital Corp II” on June 26, 2019, and to Skillsoft Corp. on June 11, 2021 (upon completion of our business combination with Software Luxembourg Holding S.A.). OVERVIEW Skillsoft® provides a skills management platform and associated learning solutions that are designed to help organizations manage the human and artificial intelligence (“AI”) skills lifecycle, including visibility into the skills they have and the skills they need, closing skills gaps, matching skills to work, and understanding how skills development impacts business performance. Organizations are operating in an environment characterized by rapid technological change, including the adoption of AI. While AI systems can generate information and automate tasks, we feel that enterprises benefit from structured systems to develop, measure, and govern both human and AI-enabled capabilities within controlled environments.

Financial trend for Skillsoft Corp. from annual reports, periods 2023-01-31 to 2026-01-31: net income (loss) went from -$724.96 million (2023-01-31) to -$139.82 million (2026-01-31), a change of +80.7%; total assets went from $1.64 billion (2023-01-31) to $963.12 million (2026-01-31), a change of -41.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1774675, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Skillsoft Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Skillsoft Corp. (CIK 1774675) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-09, and the most recent 10-K annual report was filed 2026-04-07. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 85 8-K or 6-K reports in Skillsoft Corp.’s recent EDGAR index, the 4 listed here run from 2026-07-08 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1774675 is on the EDGAR company page; the latest 10-K there is dated 2026-04-07 and the oldest filing in the recent index dates from 2019-05-03. Insider trades for Skillsoft Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Suburban propane partners sph latest news october 2026

This section ties “Suburban propane partners sph latest news october 2026” to SUBURBAN PROPANE PARTNERS LP (ticker SPH), SEC Central Index Key 1005210, an EDGAR registrant classified as “Retail-Miscellaneous Retail” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Financial trend for SUBURBAN PROPANE PARTNERS LP from annual reports, periods 2022-09-24 to 2025-09-27: revenue went from $1.50 billion (2022-09-24) to $1.43 billion (2025-09-27), a change of -4.6%; net income (loss) went from $139.71 million (2022-09-24) to $106.57 million (2025-09-27), a change of -23.7%; total assets went from $2.10 billion (2022-09-24) to $2.30 billion (2025-09-27), a change of +9.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1005210, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures SUBURBAN PROPANE PARTNERS LP did not tag for that period.

For the latest news, the fastest official source is the filing feed: SUBURBAN PROPANE PARTNERS LP (CIK 1005210) filed 271 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-22, and its overall latest filing is a 8-K dated 2026-10-22. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 271 8-K or 6-K reports in SUBURBAN PROPANE PARTNERS LP’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, SUBURBAN PROPANE PARTNERS LP most often filed 4 (463), 8-K (271), 10-Q (49), 144 (29). A selection from 2026-09-10 to 2026-10-07:

The full record for CIK 1005210 is on the EDGAR company page; the latest 10-K there is dated 2025-11-26 and the oldest filing in the recent index dates from 2010-06-17. Insider trades for SUBURBAN PROPANE PARTNERS LP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tejon ranch co. bullish and bearish analyst opinions

This section ties “Tejon ranch co. bullish and bearish analyst opinions” to TEJON RANCH CO (ticker TRC), SEC Central Index Key 96869, an EDGAR registrant classified as “Real Estate” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-19 by TEJON RANCH CO (CIK 96869) — source document:

We are a diversified real estate development company anchored by the Tejon Ranch Commerce Center (“TRCC”), a 20 million-square-foot commercial and industrial development strategically located along Interstate 5 at the gateway between the Los Angeles Basin and California’s Central Valley. TRCC is the primary driver of our revenue and earnings. TRC’s portfolio within TRCC comprises approximately 3.4 million square feet of gross leasable area, which is substantially fully leased to nationally recognized tenants, including IKEA, L’Oréal, and Dollar General. In addition, the broader TRCC development, totaling over 8 million square feet, includes major third-party industrial users such as Caterpillar and Nestlé, further reinforcing the scale, quality, and strategic importance of the park.

Financial trend for TEJON RANCH CO from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $15.81 million (2022-12-31) to $75,000 (2025-12-31), a change of -99.5%; total assets went from $566.79 million (2022-12-31) to $630.47 million (2025-12-31), a change of +11.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 96869, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TEJON RANCH CO did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TEJON RANCH CO (CIK 96869) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 102 8-K or 6-K reports in TEJON RANCH CO’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 96869 is on the EDGAR company page; the latest 10-K there is dated 2026-03-19 and the oldest filing in the recent index dates from 2013-05-10. Insider trades for TEJON RANCH CO appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tenaya therapeutics, inc. bullish and bearish analyst opinions

This section ties “Tenaya therapeutics, inc. bullish and bearish analyst opinions” to Tenaya Therapeutics, Inc. (ticker TNYA), SEC Central Index Key 1858848, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a DEFA14A dated 2026-10-23. Nothing here is a recommendation to trade the security.

Financial trend for Tenaya Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$123.67 million (2022-12-31) to -$90.60 million (2025-12-31), a change of +26.7%; total assets went from $278.94 million (2022-12-31) to $146.92 million (2025-12-31), a change of -47.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1858848, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Tenaya Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Tenaya Therapeutics, Inc. (CIK 1858848) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-03-11. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 53 8-K or 6-K reports in Tenaya Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-29 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 351 recent EDGAR filings, Tenaya Therapeutics, Inc. most often filed 4 (124), 8-K (53), 144 (26), 3 (20). A selection from 2026-09-11 to 2026-10-23:

The full record for CIK 1858848 is on the EDGAR company page; the latest 10-K there is dated 2026-03-11 and the oldest filing in the recent index dates from 2021-05-07. Insider trades for Tenaya Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Travelzoo bullish and bearish analyst opinions

This section ties “Travelzoo bullish and bearish analyst opinions” to TRAVELZOO (ticker TZOO), SEC Central Index Key 1133311, an EDGAR registrant classified as “Services-Advertising” and organised in DE, formerly known as TRAVELZOO INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-30. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-11 by TRAVELZOO (CIK 1133311) — source document:

Travelzoo (including its subsidiaries and affiliates, the “Company” or “we”) is a global Internet media company. We operate Travelzoo®, the club for travel enthusiasts, Jack’s Flight Club®, and Travelzoo META. We reach 30 million travelers. Club Members, who pay a membership fee, receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel suppliers—give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a travel enthusiast. Travelzoo attracts a high-quality audience of travel enthusiasts across multiple digital platforms, including email, websites, social media and mobile applications. We have over 4.7 million social media followers on Facebook, Instagram, X and WeChat and, to date, our iOS and An droid mobile applications have been downloaded 8.1 million times.

Financial trend for TRAVELZOO from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $6.63 million (2022-12-31) to $4.70 million (2025-12-31), a change of -29.2%; total assets went from $67.27 million (2022-12-31) to $45.19 million (2025-12-31), a change of -32.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1133311, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TRAVELZOO did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TRAVELZOO (CIK 1133311) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-28, and the most recent 10-K annual report was filed 2026-03-11. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 184 8-K or 6-K reports in TRAVELZOO’s recent EDGAR index, the 4 listed here run from 2026-02-19 to 2026-07-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1133311 is on the EDGAR company page; the latest 10-K there is dated 2026-03-11 and the oldest filing in the recent index dates from 2005-04-29. Insider trades for TRAVELZOO appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tvardi therapeutics, inc. bullish and bearish analyst opinions

This section ties “Tvardi therapeutics, inc. bullish and bearish analyst opinions” to Tvardi Therapeutics, Inc. (ticker TVRD), SEC Central Index Key 1346830, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as Cara Therapeutics, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Tvardi Therapeutics, Inc. (CIK 1346830) — source document:

We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders ’ seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing. ​ Our pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is our first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC).

Financial trend for Tvardi Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$85.47 million (2022-12-31) to -$18.21 million (2025-12-31), a change of +78.7%; total assets went from $182.24 million (2022-12-31) to $32.07 million (2025-12-31), a change of -82.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1346830, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Tvardi Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Tvardi Therapeutics, Inc. (CIK 1346830) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 146 8-K or 6-K reports in Tvardi Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-07 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1346830 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2005-12-06. Insider trades for Tvardi Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Usa compression partners usac news october 2026

This section ties “Usa compression partners usac news october 2026” to USA Compression Partners, LP (ticker USAC), SEC Central Index Key 1522727, an EDGAR registrant classified as “Natural Gas Transmission” and organised in TX. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-17 by USA Compression Partners, LP (CIK 1522727) — source document:

USA Compression Partners, LP (the “Partnership”) is a growth-oriented Delaware limited partnership. We are managed by our general partner, USA Compression GP, LLC (the “General Partner”), which is wholly owned by Energy Transfer. We have been providing compression services since 1998 and completed our initial public offering in January 2013. As of December 31, 2025, we had 3.9 million horsepower in our fleet. On January 12, 2026, we acquired all of the equity interests in J-W Energy Company (“J-W Energy”) and its subsidiary, J-W Power Company (“J-W Power”), which acquisition we refer to as the J-W Power Acquisition. An additional 1.0 million horsepower was added to our fleet through the J-W Power Acquisition.

Financial trend for USA Compression Partners, LP from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $30.32 million (2022-12-31) to $111.32 million (2025-12-31), a change of +267.2%; total assets went from $2.67 billion (2022-12-31) to $2.62 billion (2025-12-31), a change of -1.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1522727, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures USA Compression Partners, LP did not tag for that period.

For the latest news, the fastest official source is the filing feed: USA Compression Partners, LP (CIK 1522727) filed 138 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-05, and its overall latest filing is a SCHEDULE 13G/A dated 2026-10-07. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 138 8-K or 6-K reports in USA Compression Partners, LP’s recent EDGAR index, the 4 listed here run from 2026-09-10 to 2026-10-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1522727 is on the EDGAR company page; the latest 10-K there is dated 2026-02-17 and the oldest filing in the recent index dates from 2011-06-09. Insider trades for USA Compression Partners, LP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Vestis corporation commercial services & supplies news

This section ties “Vestis corporation commercial services & supplies news” to Vestis Corp (ticker VSTS), SEC Central Index Key 1967649, an EDGAR registrant classified as “Wholesale-Miscellaneous Nondurable Goods” and organised in DE, formerly known as Epic NewCo, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2025-12-02 by Vestis Corp (CIK 1967649) — source document:

Vestis Corporation, a Delaware Corporation (“Vestis”, the “Company”, “our”, “we” or “us”) is a leading provider of uniform rentals and workplace supplies across the United States and Canada. We provide uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products and other workplace supplies. In fiscal year 2025, we generated revenue of approximately $2.7 billion. We are one of the largest companies operating within the United States and Canada in our industry. We have over 75 years of experience providing uniforms and workplace supplies and a broad footprint that supports efficient delivery of our services and products to more than 300,000 customer accounts (based on unique customer identification numbers) across the United States and Canada.

Financial trend for Vestis Corp from annual reports, periods 2022-09-30 to 2025-10-03: revenue went from $2.69 billion (2022-09-30) to $2.73 billion (2025-10-03), a change of +1.8%; net income (loss) went from $141.68 million (2022-09-30) to -$40.22 million (2025-10-03), a change of -128.4%; total assets went from $3.16 billion (2023-09-29) to $2.91 billion (2025-10-03), a change of -7.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1967649, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Vestis Corp did not tag for that period.

For the latest news, the fastest official source is the filing feed: Vestis Corp (CIK 1967649) filed 42 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-28, and its overall latest filing is a 4 dated 2026-10-07. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 42 8-K or 6-K reports in Vestis Corp’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-09-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1967649 is on the EDGAR company page; the latest 10-K there is dated 2025-12-02 and the oldest filing in the recent index dates from 2023-03-17. Insider trades for Vestis Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Visionsys ai inc. bullish and bearish analyst opinions

This section ties “Visionsys ai inc. bullish and bearish analyst opinions” to VisionSys AI Inc (ticker VSA), SEC Central Index Key 1592560, an EDGAR registrant classified as “Services-Educational Services” and organised in Cayman Islands, formerly known as TCTM Kids IT Education Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-07-10. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-05-11 by VisionSys AI Inc (CIK 1592560) — source document:

We began our operations in Beijing in September 2002 through Beijing Tarena Technology Co., Ltd. In November 2012, we changed the name of Beijing Tarena Technology Co., Ltd. to Tarena Technologies Inc., or Tarena Tech. Tarena International, Inc., an exempted company with limited liability, was incorporated in the Cayman Islands in October 2003 and became our ultimate holding company. On April 3, 2014, our American depositary shares, or ADSs, began trading on Nasdaq under the ticker symbol “TEDU” in connection with our initial public offering. We historically focused on the provision of IT and STEM education services before Divestiture 2024 and Deposition 2025. In recent years, we undertook a series of strategic transactions to streamline our operations and reposition our business.

Financial trend for VisionSys AI Inc from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2025-12-31 at 1,039,000 CNY; net income (loss) was tagged only for 2025-12-31 at $245.80 million; total assets went from 1,337,500,000 CNY (2022-12-31) to 106,562,000 CNY (2025-12-31), a change of -92.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1592560, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures VisionSys AI Inc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on VisionSys AI Inc (CIK 1592560) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-05-11. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 136 8-K or 6-K reports in VisionSys AI Inc’s recent EDGAR index, the 4 listed here run from 2026-04-21 to 2026-07-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1592560 is on the EDGAR company page; the latest 20-F there is dated 2026-05-11 and the oldest filing in the recent index dates from 2013-11-26. Insider trades for VisionSys AI Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

1stdibs.com, inc. bullish and bearish analyst opinions

This section ties “1stdibs.com, inc. bullish and bearish analyst opinions” to 1stdibs.com, Inc. (ticker DIBS), SEC Central Index Key 1600641, an EDGAR registrant classified as “Retail-Catalog & Mail-Order Houses” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D/A dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-27 by 1stdibs.com, Inc. (CIK 1600641) — source document:

We are one of the world’s leading online marketplaces for connecting design lovers with many of the best sellers and makers of vintage, antique, and contemporary furniture, home décor, jewelry, watches, art, and fashion. We believe we are a leading online marketplace for these luxury design items based on the aggregate number of listings on our online marketplace and our Gross Merchandise Value (“GMV”). Our sellers, who undergo an evaluation by our in-house experts to vet the quality of their inventory, in-depth marketing content, and custom-built technology platform create trust in our brand and facilitate high-consideration purchases of luxury design items online. By disrupting the way these items are bought and sold, we are both expanding access to, and growing the market for, luxury design. 1stDibs began over two decades ago with the vision of bringing the magic of the Paris flea market online by creating a listings site for top vintage and antique furniture sellers.

Financial trend for 1stdibs.com, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $96.85 million (2022-12-31) to $89.62 million (2025-12-31), a change of -7.5%; net income (loss) went from -$22.54 million (2022-12-31) to -$13.67 million (2025-12-31), a change of +39.4%; total assets went from $195.80 million (2022-12-31) to $132.11 million (2025-12-31), a change of -32.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1600641, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures 1stdibs.com, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on 1stdibs.com, Inc. (CIK 1600641) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for 1stdibs.com, Inc. (CIK 1600641) lists its business address as 300 PARK AVENUE SOUTH, NEW YORK, NY, which helps confirm you are on the right company’s site.

Current reports. Of the 41 8-K or 6-K reports in 1stdibs.com, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-11 to 2026-09-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1600641 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2014-02-25. Insider trades for 1stdibs.com, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

51talk online education group bullish and bearish analyst opinions

This section ties “51talk online education group bullish and bearish analyst opinions” to 51Talk Online Education Group (ticker COE), SEC Central Index Key 1659494, an EDGAR registrant classified as “Services-Educational Services” and organised in Cayman Islands, formerly known as China Online Education Group. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D/A dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-23 by 51Talk Online Education Group (CIK 1659494) — source document:

In order to facilitate international capital raising of our company, we incorporated China Online Education Group, or 51Talk, to become our offshore holding company under the laws of the Cayman Islands in November 2012. In October 2014, 51Talk English International Limited, or COE HK Co, was incorporated with limited liability in Hong Kong. In the Philippines, we incorporated two limited liability companies: China Online Innovations Inc., or Philippines Co II, and On Demand English Innovations Inc., or Philippines Co III, which were incorporated in October 2014 and January 2016, respectively. Furthermore, we began to enter into employment agreements with office-based tutors and other full-time employees in the Philippines through Philippines Co II and with the free trial tutors and support staff through Philippines Co III. On June 10, 2016, our ADSs began trading on the NYSE under the ticker symbol “COE.” We sold a total of 2,760,000 ADSs (reflecting the full exercise of the over-allotment option by the underwriters to purchase an additional 360,000 ADSs), representing 41,400,000 Class A ordinary shares, at an initial offering price of US$19.00 per ADS.

Financial trend for 51Talk Online Education Group from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $15.05 million (2022-12-31) to $95.60 million (2025-12-31), a change of +535.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1659494, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures 51Talk Online Education Group did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on 51Talk Online Education Group (CIK 1659494) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 63 8-K or 6-K reports in 51Talk Online Education Group’s recent EDGAR index, the 4 listed here run from 2025-12-08 to 2026-09-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1659494 is on the EDGAR company page; the latest 20-F there is dated 2026-04-23 and the oldest filing in the recent index dates from 2015-12-21. Insider trades for 51Talk Online Education Group appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Abundia global impact group inc. bullish and bearish analyst opinions

This section ties “Abundia global impact group inc. bullish and bearish analyst opinions” to ABUNDIA GLOBAL IMPACT GROUP, INC. (ticker AGIG), SEC Central Index Key 1156041, an EDGAR registrant classified as “Crude Petroleum & Natural Gas” and organised in DE, formerly known as HOUSTON AMERICAN ENERGY CORP. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-08-26. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-23 by ABUNDIA GLOBAL IMPACT GROUP, INC. (CIK 1156041) — source document:

On July 1, 2025, Abundia Global Impact Group, Inc. (formerly Houston American Energy Corp.), a Delaware corporation (“AGIG”, the “Company,” “we,” “us,” or “our”), acquired all of the outstanding units of Abundia Global Impact Group LLC (“AGIG LLC”) through a share exchange transaction. Prior to the transaction, the Company, as Houston American Energy Corp. (“HUSA”), operated as a small independent oil and gas company focused on the exploration and production of crude oil and natural gas primarily in the Permian Basin and the U.S. Gulf Coast region. For accounting purposes, the Share Exchange is treated as a reverse acquisition, with AGIG as the surviving entity. As such, the historical financial statements of the accounting acquirer, AGIG, became the historical consolidated financial statements of the Company.

Financial trend for ABUNDIA GLOBAL IMPACT GROUP, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.64 million (2022-12-31) to $410,632 (2025-12-31), a change of -74.9%; net income (loss) went from -$744,279 (2022-12-31) to -$29.45 million (2025-12-31), a change of -3857.2%; total assets went from $11.73 million (2022-12-31) to $31.86 million (2025-12-31), a change of +171.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1156041, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ABUNDIA GLOBAL IMPACT GROUP, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ABUNDIA GLOBAL IMPACT GROUP, INC. (CIK 1156041) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2025-11-10, and the most recent 10-K annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 227 8-K or 6-K reports in ABUNDIA GLOBAL IMPACT GROUP, INC.’s recent EDGAR index, the 4 listed here run from 2026-05-18 to 2026-08-26, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1156041 is on the EDGAR company page; the latest 10-K/A there is dated 2026-05-13 and the oldest filing in the recent index dates from 2001-08-03. Insider trades for ABUNDIA GLOBAL IMPACT GROUP, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Acadian timber corp. bullish and bearish analyst opinions

What this search refers to. Acadian Timber Corp. is a Canadian timberland owner in New Brunswick, Nova Scotia and Maine that has been listed on the Toronto Stock Exchange; Canadian issuers file through SEDAR+, not EDGAR. Official source: www.sedarplus.ca.

No SEC filer could be matched to “Acadian timber corp. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Acadian timber corp.” appears in 4136+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “acadian” (search terms considered: acadian, timber).

In the 100 most relevant full-text hits returned for “Acadian timber corp.”, filings range from 2013-08-16 to 2026-09-24. The filers whose documents mention it most often are SCHULHOFF & CO INC (CIK 0001080197) (47 hits); DFA INVESTMENT TRUST CO (CIK 0000896162) (25 hits); Broderick Brian C (CIK 0001314376) (17 hits); DELAWARE POOLED TRUST (CIK 0000875352) (9 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

Word by word, the number of EDGAR registrant names containing each term of this search is: “acadian” 100, “timber” 195. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “acadian” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Akari therapeutics, plc bullish and bearish analyst opinions

This section ties “Akari therapeutics, plc bullish and bearish analyst opinions” to Akari Therapeutics Plc (ticker AKTX), SEC Central Index Key 1541157, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in United Kingdom, formerly known as Celsus Therapeutics Plc.. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-16. Nothing here is a recommendation to trade the security.

Financial trend for Akari Therapeutics Plc from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$17.75 million (2022-12-31) to -$17.30 million (2025-12-31), a change of +2.5%; total assets went from $13.83 million (2022-12-31) to $47.89 million (2025-12-31), a change of +246.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1541157, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Akari Therapeutics Plc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Akari Therapeutics Plc (CIK 1541157) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 250 8-K or 6-K reports in Akari Therapeutics Plc’s recent EDGAR index, the 4 listed here run from 2026-06-26 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 741 recent EDGAR filings, Akari Therapeutics Plc most often filed 6-K (188), 4 (97), 8-K (62), EFFECT (50). A selection from 2026-10-16 to 2026-10-16:

The full record for CIK 1541157 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2012-04-13. Insider trades for Akari Therapeutics Plc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aktis oncology, inc. bullish and bearish analyst opinions

This section ties “Aktis oncology, inc. bullish and bearish analyst opinions” to Aktis Oncology, Inc. (ticker AKTS), SEC Central Index Key 2035832, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-24. Nothing here is a recommendation to trade the security.

Financial trend for Aktis Oncology, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $1.60 million (2025-06-30) to $3.38 million (2026-06-30), a change of +111.4%; net income (loss) went from -$18.07 million (2025-06-30) to -$24.14 million (2026-06-30), a change of -33.6%; total assets went from $576.80 million (2026-03-31) to $557.60 million (2026-06-30), a change of -3.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2035832, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Aktis Oncology, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Aktis Oncology, Inc. (CIK 2035832) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 5 8-K or 6-K reports in Aktis Oncology, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-30 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 62 recent EDGAR filings, Aktis Oncology, Inc. most often filed 3 (17), 4 (13), 144 (5), 8-K (5). A selection from 2026-07-20 to 2026-09-24:

The full record for CIK 2035832 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2024-10-02. Insider trades for Aktis Oncology, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Allarity therapeutics, inc. bullish and bearish analyst opinions

This section ties “Allarity therapeutics, inc. bullish and bearish analyst opinions” to Allarity Therapeutics, Inc. (ticker ALLR), SEC Central Index Key 1860657, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-09, and this view starts from filings dated on or before 2026-05-15. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by Allarity Therapeutics, Inc. (CIK 1860657) (passage 2, continuing from the earlier excerpt) — source document:

Ideally, by using DRP to identify the patients most likely to benefit clinically from a given therapeutic, clinical development of that therapeutic can be focused on a smaller, more responsive patient population, which would allow for smaller, cheaper and quicker trials while also enhancing the probability of clinical and regulatory success for that therapeutic. Historically, we have generated DRP signatures for numerous anti-cancer therapeutics and had in-licensed numerous assets for DRP-guided development, including Liposomal CisPlatin (LiPlaCis), Irofulven and dovitinib as well as the novel PARP/tankyrase inhibitor, stenoparib. During 2024, Thomas H. Jensen, co-founder of Allarity, was permanently installed as Chief Executive Officer due to his extensive experience not only with the core DRP® platform technology but also with capital fund raising.

Financial trend for Allarity Therapeutics, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $25,000 (2026-03-31) to $0 (2026-06-30), a change of -100.0%; net income (loss) went from -$2.81 million (2025-09-30) to -$3.40 million (2026-06-30), a change of -21.3%; total assets went from $20.80 million (2025-09-30) to $32.12 million (2026-06-30), a change of +54.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1860657, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 3 periods shown, dashes mark figures Allarity Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Allarity Therapeutics, Inc. (CIK 1860657) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 153 8-K or 6-K reports in Allarity Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-02 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1860657 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2021-05-27. One example from this record is the 8-K filed 2026-09-14 (document). Insider trades for Allarity Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ashford hospitality trust, inc. bullish and bearish analyst opinions

This section ties “Ashford hospitality trust, inc. bullish and bearish analyst opinions” to ASHFORD HOSPITALITY TRUST INC (ticker AHT, AHT-PD, AHT-PF, AHT-PG, AHT-PH, AHT-PI), SEC Central Index Key 1232582, an EDGAR registrant classified as “Real Estate Investment Trusts” and organised in MD. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-23 by ASHFORD HOSPITALITY TRUST INC (CIK 1232582) — source document:

Ashford Hospitality Trust, Inc., together with its subsidiaries is a REIT. While our portfolio currently consists of upscale hotels and upper upscale full-service hotels, our investment strategy is predominantly focused on investing in upper upscale full-service hotels in the United States that have revenue per available room (“RevPAR”) generally less than twice the U.S. national average, and in all methods including direct real estate, equity and debt. We currently anticipate future investments will predominantly be in upper upscale hotels. We own our lodging investments and conduct our business through Ashford Hospitality Limited Partnership (“Ashford Trust OP”), our operating partnership. Ashford OP General Partner LLC, a wholly owned subsidiary of Ashford Trust, serves as the sole general partner of our operating partnership.

Financial trend for ASHFORD HOSPITALITY TRUST INC from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$139.82 million (2022-12-31) to -$179.84 million (2025-12-31), a change of -28.6%; total assets went from $3.92 billion (2022-12-31) to $2.83 billion (2025-12-31), a change of -27.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1232582, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ASHFORD HOSPITALITY TRUST INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ASHFORD HOSPITALITY TRUST INC (CIK 1232582) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 389 8-K or 6-K reports in ASHFORD HOSPITALITY TRUST INC’s recent EDGAR index, the 4 listed here run from 2026-08-27 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1232582 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2018-02-05. Insider trades for ASHFORD HOSPITALITY TRUST INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Averin capital acquisition corp. bullish and bearish analyst opinions

This section ties “Averin capital acquisition corp. bullish and bearish analyst opinions” to Averin Capital Acquisition Corp. (ticker ACAA, ACAAU, ACAAW), SEC Central Index Key 2096900, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-16. Nothing here is a recommendation to trade the security.

Financial trend for Averin Capital Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $832,500 (2026-03-31) to $2.36 million (2026-06-30), a change of +182.9%; total assets went from $285.52 million (2026-03-31) to $287.92 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2096900, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Averin Capital Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Averin Capital Acquisition Corp. (CIK 2096900) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Averin Capital Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 2 such filings (424B4, S-1) appear in its recent index, the newest dated 2026-02-18.

Current reports. Of the 6 8-K or 6-K reports in Averin Capital Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2026-03-05 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 27 recent EDGAR filings, Averin Capital Acquisition Corp. most often filed 3 (7), 8-K (6), 10-Q (2), SCHEDULE 13G (2). A selection from 2026-03-04 to 2026-08-05:

The full record for CIK 2096900 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-11-17. Insider trades for Averin Capital Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Betterware de mexico, s.a.p.i. de c.v. bullish and bearish analyst opinions

This section ties “Betterware de mexico, s.a.p.i. de c.v. bullish and bearish analyst opinions” to BETTERWARE DE MEXICO, S.A.P.I. DE C.V (ticker BWMX), SEC Central Index Key 1788257, an EDGAR registrant classified as “Retail-Catalog & Mail-Order Houses” and organised in Mexico, formerly known as Betterware de Mexico, S.A.B. de C.V.. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-30 by BETTERWARE DE MEXICO, S.A.P.I. DE C.V (CIK 1788257) — source document:

Betterware de México, S.A.P.I. de C.V. (formerly Betterware de México, S.A.B. de C.V.), is a Mexican sociedad anónima promotora de inversión de capital variable that was incorporated under the laws of Mexico in 1995. The company’s headquarters are located in the city of Jalisco, Mexico, and its main registered office is located at Gdl-Ameca-Huaxtla km-5, El Arenal Jalisco, 45350, México, and the telephone number is +52 (33) 3836-0500. Our agent for service of process in the United States is Corporate Services Company (“CSC”), located at 251 Little Falls Drive, Wilmington, Delaware 19808-1674. The Company’s shares are listed on the New York Stock Exchange (“NYSE”) under the trading symbol “BWMX.” The Company makes its filings in electronic form under the EDGAR filing system of the SEC. Our filings are available through the EDGAR system at www.sec.gov.

Financial trend for BETTERWARE DE MEXICO, S.A.P.I. DE C.V from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from 10,039,668,000 MXN (2021-12-31) to 14,100,758,000 MXN (2024-12-31), a change of +40.5%; net income (loss) went from 1,800,884,000 MXN (2021-12-31) to 711,522,000 MXN (2024-12-31), a change of -60.5%; total assets went from 5,185,229,000 MXN (2021-12-31) to 10,453,767,000 MXN (2024-12-31), a change of +101.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1788257, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures BETTERWARE DE MEXICO, S.A.P.I. DE C.V did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BETTERWARE DE MEXICO, S.A.P.I. DE C.V (CIK 1788257) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 81 8-K or 6-K reports in BETTERWARE DE MEXICO, S.A.P.I. DE C.V’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1788257 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2019-09-27. Insider trades for BETTERWARE DE MEXICO, S.A.P.I. DE C.V appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Braemar hotels & resorts inc. bullish and bearish analyst opinions

This section ties “Braemar hotels & resorts inc. bullish and bearish analyst opinions” to Braemar Hotels & Resorts Inc. (ticker BHR, BHR-PB, BHR-PD), SEC Central Index Key 1574085, an EDGAR registrant classified as “Real Estate Investment Trusts” and organised in MD, formerly known as Ashford Hospitality Prime, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-12 by Braemar Hotels & Resorts Inc. (CIK 1574085) — source document:

We are an externally-advised Maryland corporation formed in 2013 that invests primarily in high revenue per available room (“RevPAR”) luxury hotels and resorts. High RevPAR, for purposes of our investment strategy, means RevPAR of at least twice the then-current U.S. national average RevPAR for all hotels as determined by STR, LLC. Two times the U.S. national average RevPAR was approximately $200 for the year ended December 31, 2025. We have elected to be taxed as a REIT under the Code beginning in the year ended December 31, 2013. We conduct our business and own substantially all of our assets through our operating partnership, Braemar OP. We operate in the direct hotel investment segment of the hotel lodging industry.

Financial trend for Braemar Hotels & Resorts Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $17.76 million (2022-12-31) to -$22.32 million (2025-12-31), a change of -225.7%; total assets went from $2.40 billion (2022-12-31) to $1.86 billion (2025-12-31), a change of -22.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1574085, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Braemar Hotels & Resorts Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Braemar Hotels & Resorts Inc. (CIK 1574085) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 395 8-K or 6-K reports in Braemar Hotels & Resorts Inc.’s recent EDGAR index, the 4 listed here run from 2026-10-08 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1574085 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-29 and the oldest filing in the recent index dates from 2017-01-25. Insider trades for Braemar Hotels & Resorts Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bridger aerospace group holdings, inc. common stock bullish and bearish analyst opinions

This section ties “Bridger aerospace group holdings, inc. common stock bullish and bearish analyst opinions” to Bridger Aerospace Group Holdings, Inc. (ticker BAER, BAERW), SEC Central Index Key 1941536, an EDGAR registrant classified as “Services-Business Services, NEC” and organised in DE, formerly known as Wildfire New PubCo, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-06 by Bridger Aerospace Group Holdings, Inc. (CIK 1941536) — source document:

Bridger provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods primarily throughout the United States, as well as airframe modification and integration solutions for governmental and commercial customers. Our mission is to deploy the most advanced technologies in aviation to protect lives, property, critical infrastructure, and the environment, delivering these capabilities where they are needed most, from wildfire response to defense and beyond. Through innovation and the use of advanced technology and software, focusing on aerial firefighting, disaster response, government applications and public safety, Bridger aims to set the global standard in aviation services. Bridger was founded in 2014 in Bozeman, Montana by Tim Sheehy, former U.S. Navy SEAL officer and current United States Senator.

Financial trend for Bridger Aerospace Group Holdings, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $46.39 million (2022-12-31) to $122.83 million (2025-12-31), a change of +164.8%; net income (loss) went from -$42.12 million (2022-12-31) to $4.14 million (2025-12-31), a change of +109.8%; total assets went from $305.98 million (2022-12-31) to $330.31 million (2025-12-31), a change of +8.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1941536, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Bridger Aerospace Group Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Bridger Aerospace Group Holdings, Inc. (CIK 1941536) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Bridger Aerospace Group Holdings, Inc. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 40 such filings (424B3, 424B5, 425, S-1, S-1/A) appear in its recent index, the newest dated 2025-03-19.

Current reports. Of the 47 8-K or 6-K reports in Bridger Aerospace Group Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-05 to 2026-09-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1941536 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2022-08-08. Insider trades for Bridger Aerospace Group Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bristol-myers squibb company ce bullish and bearish analyst opinions

This section ties “Bristol-myers squibb company ce bullish and bearish analyst opinions” to BRISTOL MYERS SQUIBB CO (ticker BMY, CELG-RI), SEC Central Index Key 14272, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-11 by BRISTOL MYERS SQUIBB CO (CIK 14272) — source document:

Mine Safety Disclosures 37 PART IA Information about our Executive Officers 37 PART II Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 39 Item 6. [Reserved] 40 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 41 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 71 Item 8. Financial Statements and Supplementary Data 73 Consolidated Statements of Earnings and Comprehensive Income/(Loss) 73 Consolidated Balance Sheets 74 Consolidated Statements of Cash Flows 75 Notes to the Financial Statements 76 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 123 Item 9A. Controls and Procedures 123 Item 9B. Other Information 123 Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 123 PART III Item 10.

Financial trend for BRISTOL MYERS SQUIBB CO from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $46.16 billion (2022-12-31) to $48.19 billion (2025-12-31), a change of +4.4%; net income (loss) went from $6.33 billion (2022-12-31) to $7.05 billion (2025-12-31), a change of +11.5%; total assets went from $96.82 billion (2022-12-31) to $90.04 billion (2025-12-31), a change of -7.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 14272, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BRISTOL MYERS SQUIBB CO did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BRISTOL MYERS SQUIBB CO (CIK 14272) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-30, and the most recent 10-K annual report was filed 2026-02-11. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 122 8-K or 6-K reports in BRISTOL MYERS SQUIBB CO’s recent EDGAR index, the 4 listed here run from 2026-02-05 to 2026-07-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 14272 is on the EDGAR company page; the latest 10-K there is dated 2026-02-11 and the oldest filing in the recent index dates from 2019-03-26. Insider trades for BRISTOL MYERS SQUIBB CO appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cenntro electric group limited bullish and bearish analyst opinions

This section ties “Cenntro electric group limited bullish and bearish analyst opinions” to Cenntro Inc. (ticker CENN), SEC Central Index Key 1707919, an EDGAR registrant classified as “Motor Vehicles & Passenger Car Bodies” and organised in NV, formerly known as CENNTRO ELECTRIC GROUP Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K/A dated 2026-10-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-15 by Cenntro Inc. (CIK 1707919) — source document:

We are an emerging designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. Our commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery and other commercial applications. As of December 31, 2025, we have developed six series of commercial vehicle models, Metro®, Logistar™, iChassis™, Avantier™, Teemak™, Bison Motor™ and Antric One. We have successfully begun to produce and deliver these models into the global markets, apart from Logimax™. We have also developed and introduced iChassis™ platform that consists of a programmable “smart” chassis that is currently used by third parties and integrated with their controlling software for various autonomous driving commercial vehicle applications.

Financial trend for Cenntro Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $8.94 million (2022-12-31) to $18.08 million (2025-12-31), a change of +102.2%; net income (loss) went from -$110.09 million (2022-12-31) to -$72.98 million (2025-12-31), a change of +33.7%; total assets went from $267.85 million (2022-12-31) to $74.43 million (2025-12-31), a change of -72.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1707919, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Cenntro Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Cenntro Inc. (CIK 1707919) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-04-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 147 8-K or 6-K reports in Cenntro Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-28 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1707919 is on the EDGAR company page; the latest 10-K there is dated 2026-04-15 and the oldest filing in the recent index dates from 2017-07-27. Insider trades for Cenntro Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Chemomab therapeutics ltd. bullish and bearish analyst opinions

This section ties “Chemomab therapeutics ltd. bullish and bearish analyst opinions” to Chemomab Therapeutics Ltd. (ticker CMMB), SEC Central Index Key 1534248, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Israel, formerly known as Anchiano Therapeutics Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-23 by Chemomab Therapeutics Ltd. (CIK 1534248) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 64 A. Operating Results 65 B. Liquidity and Capital Resources 69 C. Research and Development, Patents and Licenses, Etc. 71 D. Trend Information 71 E. Critical Accounting Estimates 71 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 71 A. Directors and Senior Management 71 B. Compensation 73 C. Board Practices 77 D. Employees 86 E. Share Ownership 86 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 86 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 86 A. Major Shareholders 86 B. Related Party Transactions 88 C. Interests of Experts and Counsel 88 ITEM 8. FINANCIAL INFORMATION 88 A. Consolidated Statements and Other Financial Information 88 B. Significant Changes 89 ITEM 9.

Financial trend for Chemomab Therapeutics Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$27.65 million (2022-12-31) to -$8.99 million (2025-12-31), a change of +67.5%; total assets went from $43.06 million (2022-12-31) to $13.81 million (2025-12-31), a change of -67.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1534248, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Chemomab Therapeutics Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Chemomab Therapeutics Ltd. (CIK 1534248) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2023-05-11, and the most recent 20-F annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 111 8-K or 6-K reports in Chemomab Therapeutics Ltd.’s recent EDGAR index, the 4 listed here run from 2026-07-08 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1534248 is on the EDGAR company page; the latest 20-F there is dated 2026-03-23 and the oldest filing in the recent index dates from 2011-11-07. Insider trades for Chemomab Therapeutics Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Chow sang sang holdings international limited bullish and bearish analyst opinions

Read from its name, “Chow sang sang holdings international limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Chow sang sang holdings international limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Chow sang sang holdings international limited” appears in 959+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “chow” (search terms considered: chow, sang, sang, international).

A broader EDGAR full-text search for the shorter phrase “Chow sang sang” finds 10000+ filing documents; among the top 100, the filers mentioning it most are TWEEDY, BROWNE FUND INC. (CIK 0000896975) (53); SSGA FUNDS (CIK 0000826686) (7); Plainsboro Funds (CIK 0001521268) (7). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Chow sang sang holdings international limited”, filings range from 2010-01-29 to 2026-08-28. The filers whose documents mention it most often are JOHN HANCOCK VARIABLE INSURANCE TRUST (CIK 0000756913) (27 hits); JNL SERIES TRUST (CIK 0000933691) (14 hits); Segall Bryant & Hamill Trust (CIK 0000357204) (12 hits); WELLS FARGO MASTER TRUST (CIK 0001087961) (12 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 73 entities whose registered name contains the word “chow”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “chow” 73, “sang” 45, “sang” 45, “international” 458. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “chow” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Cibus nordic real estate ab (publ) bullish and bearish analyst opinions

“AB (publ)” marks a Swedish public limited company (aktiebolag) allowed to offer shares to the public. The name “Cibus nordic real estate ab (publ)” therefore points to a company organised in Sweden, and its official disclosures are on Nasdaq Stockholm / Spotlight announcements and the Swedish FSA (Finansinspektionen) register (www.fi.se), not on EDGAR.

No SEC filer could be matched to “Cibus nordic real estate ab (publ) bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Cibus nordic real estate ab publ” appears in 4016+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “cibus” (search terms considered: cibus, nordic, real, estate).

A broader EDGAR full-text search for the shorter phrase “Cibus nordic real” finds 8324+ filing documents; among the top 100, the filers mentioning it most are Nuveen Investment Trust V (CIK 0001380786) (16); DEUTSCHE DWS VARIABLE SERIES I (CIK 0000764797) (14); DEUTSCHE DWS GLOBAL/INTERNATIONAL FUND, INC. (CIK 0000793597) (13). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Sweden. Companies there file with Nasdaq Stockholm and Finansinspektionen rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “cibus” is therefore the Sweden regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 100 most relevant full-text hits returned for “Cibus nordic real estate ab publ”, filings range from 2022-02-28 to 2026-05-28. The filers whose documents mention it most often are iSHARES TRUST (CIK 0001100663) (18 hits); DEUTSCHE DWS GLOBAL/INTERNATIONAL FUND, INC. (CIK 0000793597) (15 hits); DEUTSCHE DWS VARIABLE SERIES I (CIK 0000764797) (15 hits); Nuveen Investment Trust V (CIK 0001380786) (9 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 9 entities whose registered name contains the word “cibus”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “cibus” 9, “nordic” 116, “real” 477, “estate” 475. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “cibus” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Dawson geophysical company bullish and bearish analyst opinions

This section ties “Dawson geophysical company bullish and bearish analyst opinions” to DAWSON GEOPHYSICAL CO (ticker DWSN), SEC Central Index Key 799165, an EDGAR registrant classified as “Oil & Gas Field Exploration Services” and organised in TX, formerly known as TGC INDUSTRIES INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by DAWSON GEOPHYSICAL CO (CIK 799165) — source document:

Except as otherwise specifically noted herein, references in this annual report on Form 10-K to the “Company,” “we,” “us” or “our” refer to Dawson Geophysical Company and its consolidated subsidiaries. Dawson Geophysical Company, a Texas corporation (the “Company”), is a leading provider of North American onshore seismic data acquisition services with operations throughout the continental United States (“U.S.”) and Canada. We acquire and process 2-D, 3-D and multi-component seismic data for our clients, ranging from major oil and gas companies to independent oil and gas operators, providers of multi-client data libraries and carbon capture sequestration projects. Our principal business office is located at 508 West Wall, Suite 800, Midland, Texas 79701 (Telephone: 432-684-3000), and our internet address is www.dawson3d.com.

Financial trend for DAWSON GEOPHYSICAL CO from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$18.64 million (2022-12-31) to -$1.94 million (2025-12-31), a change of +89.6%; total assets went from $68.67 million (2022-12-31) to $56.01 million (2025-12-31), a change of -18.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 799165, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures DAWSON GEOPHYSICAL CO did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on DAWSON GEOPHYSICAL CO (CIK 799165) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 242 8-K or 6-K reports in DAWSON GEOPHYSICAL CO’s recent EDGAR index, the 4 listed here run from 2025-11-12 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 799165 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2004-11-10. Insider trades for DAWSON GEOPHYSICAL CO appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Eikon therapeutics, inc. common stock bullish and bearish analyst opinions

This section ties “Eikon therapeutics, inc. common stock bullish and bearish analyst opinions” to Eikon Therapeutics, Inc. (ticker EIKN), SEC Central Index Key 1861123, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Financial trend for Eikon Therapeutics, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: net income (loss) went from -$105.21 million (2025-06-30) to -$88.41 million (2026-06-30), a change of +16.0%; total assets went from $850.83 million (2026-03-31) to $779.57 million (2026-06-30), a change of -8.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1861123, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Eikon Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Eikon Therapeutics, Inc. (CIK 1861123) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 9 8-K or 6-K reports in Eikon Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-03 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 66 recent EDGAR filings, Eikon Therapeutics, Inc. most often filed 4 (14), 3 (14), 8-K (9), SCHEDULE 13G (6). A selection from 2026-08-06 to 2026-10-07:

The full record for CIK 1861123 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2021-05-13. Insider trades for Eikon Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Enanta pharmaceuticals, inc. bullish and bearish analyst opinions

This section ties “Enanta pharmaceuticals, inc. bullish and bearish analyst opinions” to ENANTA PHARMACEUTICALS INC (ticker ENTA), SEC Central Index Key 1177648, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-08-14. Nothing here is a recommendation to trade the security.

Financial trend for ENANTA PHARMACEUTICALS INC from annual reports, periods 2022-09-30 to 2025-09-30: net income (loss) went from -$121.75 million (2022-09-30) to -$81.89 million (2025-09-30), a change of +32.7%; total assets went from $375.41 million (2022-09-30) to $280.73 million (2025-09-30), a change of -25.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1177648, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ENANTA PHARMACEUTICALS INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ENANTA PHARMACEUTICALS INC (CIK 1177648) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2025-11-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 112 8-K or 6-K reports in ENANTA PHARMACEUTICALS INC’s recent EDGAR index, the 4 listed here run from 2026-06-18 to 2026-08-10, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 832 recent EDGAR filings, ENANTA PHARMACEUTICALS INC most often filed 4 (436), 8-K (112), SC 13G/A (51), 10-Q (41). A selection from 2026-07-02 to 2026-08-14:

The full record for CIK 1177648 is on the EDGAR company page; the latest 10-K there is dated 2025-11-19 and the oldest filing in the recent index dates from 2002-06-21. Insider trades for ENANTA PHARMACEUTICALS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Figx capital acquisition corp. bullish and bearish analyst opinions

This section ties “Figx capital acquisition corp. bullish and bearish analyst opinions” to FIGX Capital Acquisition Corp. (ticker FIGX, FIGXU, FIGXW), SEC Central Index Key 2059033, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-09 by FIGX Capital Acquisition Corp. (CIK 2059033) — source document:

We are a blank check company incorporated on February 20, 2025, as a Cayman Islands exempted company and formed for the purpose of effecting a Business Combination with one or more businesses or entities. While we may pursue an initial Business Combination target in any industry, we are concentrating our efforts in identifying businesses in the financial industry group (“FIG”) sector, with a focus on differentiated private wealth/asset managers positioned to become multi-asset fund managers with diversified distribution channels and global market presence. To date, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering, and (iii) searching for and consummating a Business Combination.

Financial trend for FIGX Capital Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $1.44 million (2025-09-30) to $1.25 million (2026-06-30), a change of -12.8%; total assets went from $153.42 million (2025-09-30) to $157.23 million (2026-06-30), a change of +2.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2059033, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures FIGX Capital Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on FIGX Capital Acquisition Corp. (CIK 2059033) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for FIGX Capital Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 5 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2025-06-30.

Current reports. Of the 4 8-K or 6-K reports in FIGX Capital Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2025-07-01 to 2025-11-18, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2059033 is on the EDGAR company page; the latest 10-K there is dated 2026-03-09 and the oldest filing in the recent index dates from 2025-04-01. Insider trades for FIGX Capital Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hang xiao steel structure co., ltd. bullish and bearish analyst opinions

Read from its name, “Hang xiao steel structure co., ltd.” is a China, Taiwan, Korea or Japan entity — “Co., Ltd.” is the English rendering used by limited companies across East Asia. Its accounts and exchange notices are published through the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Hang xiao steel structure co., ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Hang xiao steel structure co., ltd.” appears in 102+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “hang” (search terms considered: hang, xiao, steel, structure).

A broader EDGAR full-text search for the shorter phrase “Hang xiao steel” finds 102+ filing documents; among the top 100, the filers mentioning it most are Dimensional ETF Trust (CIK 0001816125) (90); Krane Shares Trust (CIK 0001547576) (10). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Hang xiao steel structure co., ltd.”, filings range from 2020-02-27 to 2026-09-24. The filers whose documents mention it most often are Dimensional ETF Trust (CIK 0001816125) (90 hits); Krane Shares Trust (CIK 0001547576) (10 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 41 entities whose registered name contains the word “hang”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “hang” 41, “xiao” 94, “steel” 338, “structure” 50. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “hang” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Heidmar maritime holdings corp. bullish and bearish analyst opinions

This section ties “Heidmar maritime holdings corp. bullish and bearish analyst opinions” to Heidmar Maritime Holdings Corp. (ticker HMR), SEC Central Index Key 2029471, an EDGAR registrant classified as “Deep Sea Foreign Transportation of Freight” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-09. Nothing here is a recommendation to trade the security.

Financial trend for Heidmar Maritime Holdings Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $30.06 million (2022-12-31) to $55.85 million (2025-12-31), a change of +85.8%; net income (loss) went from $16.18 million (2022-12-31) to -$22.56 million (2025-12-31), a change of -239.4%; total assets went from $47.27 million (2023-12-31) to $72.14 million (2025-12-31), a change of +52.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2029471, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Heidmar Maritime Holdings Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Heidmar Maritime Holdings Corp. (CIK 2029471) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 17 8-K or 6-K reports in Heidmar Maritime Holdings Corp.’s recent EDGAR index, the 4 listed here run from 2026-04-24 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 85 recent EDGAR filings, Heidmar Maritime Holdings Corp. most often filed 6-K (17), 4 (10), 3 (7), 424B3 (7). A selection from 2026-06-11 to 2026-09-03:

The full record for CIK 2029471 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2024-08-22. Insider trades for Heidmar Maritime Holdings Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Inhibrx biosciences inc. bullish and bearish analyst opinions

This section ties “Inhibrx biosciences inc. bullish and bearish analyst opinions” to Inhibrx Biosciences, Inc. (ticker INBX), SEC Central Index Key 2007919, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-19 by Inhibrx Biosciences, Inc. (CIK 2007919) — source document:

We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential. Recent Developments Separation from Former Parent On May 29, 2024, Inhibrx, Inc., or the Former Parent, effected the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, upon which the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of our common stock, or the Distribution.

Financial trend for Inhibrx Biosciences, Inc. from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $1.80 million (2023-12-31) to $1.30 million (2025-12-31), a change of -27.8%; net income (loss) went from -$241.36 million (2023-12-31) to -$140.06 million (2025-12-31), a change of +42.0%; total assets went from $307.89 million (2023-12-31) to $146.48 million (2025-12-31), a change of -52.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2007919, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Inhibrx Biosciences, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Inhibrx Biosciences, Inc. (CIK 2007919) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 27 8-K or 6-K reports in Inhibrx Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-16 to 2026-09-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2007919 is on the EDGAR company page; the latest 10-K there is dated 2026-03-19 and the oldest filing in the recent index dates from 2024-01-29. Insider trades for Inhibrx Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Interprivate investment partners v inc. bullish and bearish analyst opinions

This section ties “Interprivate investment partners v inc. bullish and bearish analyst opinions” to InterPrivate Investment Partners V, Inc. (ticker IPVV, IPVVU, IPVVW), SEC Central Index Key 2105274, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-13, and this view starts from filings dated on or before 2026-06-05. Nothing here is a recommendation to trade the security.

Other filings. Across its 32 recent EDGAR filings, InterPrivate Investment Partners V, Inc. most often filed 3 (7), CORRESP (6), SCHEDULE 13G (3), 8-K (3). A selection from 2026-06-03 to 2026-06-09:

The full record for CIK 2105274 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-01-27. One example from this record is the SCHEDULE 13D filed 2026-06-15 (document). Insider trades for InterPrivate Investment Partners V, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Jayud global logistics limited bullish and bearish analyst opinions

This section ties “Jayud global logistics limited bullish and bearish analyst opinions” to Jayud Global Logistics Ltd (ticker JYD), SEC Central Index Key 1938186, an EDGAR registrant classified as “Arrangement of Transportation of Freight & Cargo” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 3 dated 2026-07-06. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-20 by Jayud Global Logistics Ltd (CIK 1938186) — source document:

We are a Cayman Islands holding company and primarily conduct our operations in China through our PRC subsidiaries. We commenced our commercial operations in September 2009 through Shenzhen Jiayuda Trading Co., Ltd. In July 2015, Shenzhen Jayud Logistics Technology Co., Ltd. (previously under the name of “Shenzhen Xinyuxiang Supply Chain Co., Ltd.”) was established to optimize our resource allocation to further expand our business. On June 10, 2022, we incorporated Jayud Global Logistics Limited under the laws of the Cayman Islands as our offshore holding company to facilitate offshore financing. In June 2022, we established Jayud Global Logistics (Hong Kong) Limited, our wholly owned Hong Kong subsidiary. In September 2022, Jayud Global Logistic (Hong Kong) Limited (“JYD HK”) directly invested in Shenzhen Jayud Logistics Technology Co., Ltd. (“JYD WLKJ”) as its direct wholly-owned subsidiary.

Financial trend for Jayud Global Logistics Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 651,991,593 CNY (2022-12-31) to 600,775,492 CNY (2025-12-31), a change of -7.9%; net income (loss) went from 3,888,723 CNY (2022-12-31) to -35,600,849 CNY (2025-12-31), a change of -1015.5%; total assets went from 125,422,314 CNY (2022-12-31) to 226,403,414 CNY (2025-12-31), a change of +80.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1938186, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Jayud Global Logistics Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Jayud Global Logistics Ltd (CIK 1938186) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 37 8-K or 6-K reports in Jayud Global Logistics Ltd’s recent EDGAR index, the 4 listed here run from 2026-03-17 to 2026-05-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1938186 is on the EDGAR company page; the latest 20-F there is dated 2026-04-20 and the oldest filing in the recent index dates from 2022-09-21. Insider trades for Jayud Global Logistics Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Jin mi fang group holdings limited bullish and bearish analyst opinions

The legal-form ending in “Jin mi fang group holdings limited” is the clue: “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. A company of that kind reports in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), so the place to read its annual report and announcements is that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) — www.hkexnews.hk.

No SEC filer could be matched to “Jin mi fang group holdings limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Jin mi fang group holdings limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “jin” (search terms considered: jin, fang).

Even the shorter phrase “Jin mi fang” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (jin, fang) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 133 entities whose registered name contains the word “jin”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “jin” 133, “fang” 93. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “jin”: ALT SEI JIN (CIK 1526339), CAI JIN-YONG (CIK 1682796), CAO JIN (CIK 2128770); containing “fang”: AI FANG (CIK 1511382), BANG MAI FANG HOLDINGS (CIK 2104827), CHEN FANG (CIK 1375714). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “jin” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

K&f growth acquisition corp. ii bullish and bearish analyst opinions

This section ties “K&f growth acquisition corp. ii bullish and bearish analyst opinions” to K&F GROWTH ACQUISITION CORP. II (ticker KFII, KFIIR, KFIIU), SEC Central Index Key 2029976, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 425 dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by K&F GROWTH ACQUISITION CORP. II (CIK 2029976) — source document:

We are a blank check company incorporated on July 2, 2024 as a Cayman Islands exempted company and formed for the purpose of effecting a Business Combination with one or more businesses or entities. We may pursue an initial Business Combination in any business or industry. To date, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering, and (iii) searching for and consummating a Business Combination. As of the date of this Report, we have not entered into a definitive agreement with a specific Business Combination target. We have generated no operating revenues to date, and we do not expect that we will generate operating revenues until we consummate our initial Business Combination.

Financial trend for K&F GROWTH ACQUISITION CORP. II from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $10.20 million; total assets went from $204,624 (2024-12-31) to $300.60 million (2025-12-31), a change of +146805.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2029976, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures K&F GROWTH ACQUISITION CORP. II did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on K&F GROWTH ACQUISITION CORP. II (CIK 2029976) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for K&F GROWTH ACQUISITION CORP. II — registration statements, prospectuses and merger proxies — are filed on EDGAR; 7 such filings (424B4, 425, S-1, S-1/A) appear in its recent index, the newest dated 2026-10-23.

Current reports. Of the 7 8-K or 6-K reports in K&F GROWTH ACQUISITION CORP. II’s recent EDGAR index, the 4 listed here run from 2026-08-21 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2029976 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2024-08-22. Insider trades for K&F GROWTH ACQUISITION CORP. II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Karbon capital partners corp. bullish and bearish analyst opinions

This section ties “Karbon capital partners corp. bullish and bearish analyst opinions” to Karbon Capital Partners Corp. (ticker KBON, KBONU, KBONW), SEC Central Index Key 2088749, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-26 by Karbon Capital Partners Corp. (CIK 2088749) — source document:

There can be no assurance that future developments affecting us will be those that we have anticipated. You should not take any statement regarding past trends or activities as representation that the trends or activities will continue in the future. Accordingly, you should not put undue reliance on these situations. In addition, statements that contain “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. Although we believe that this information provides a reasonable basis for these statements, this information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information.

Financial trend for Karbon Capital Partners Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $2.79 million (2026-03-31) to $1.39 million (2026-06-30), a change of -50.1%; total assets went from $349.59 million (2026-03-31) to $352.37 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2088749, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Karbon Capital Partners Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Karbon Capital Partners Corp. (CIK 2088749) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 4 8-K or 6-K reports in Karbon Capital Partners Corp.’s recent EDGAR index, the 4 listed here run from 2025-12-11 to 2026-01-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2088749 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2025-10-02. Insider trades for Karbon Capital Partners Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Keros therapeutics, inc. bullish and bearish analyst opinions

This section ties “Keros therapeutics, inc. bullish and bearish analyst opinions” to Keros Therapeutics, Inc. (ticker KROS), SEC Central Index Key 1664710, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-29. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-04 by Keros Therapeutics, Inc. (CIK 1664710) — source document:

We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Our lead product candidate, rinvatercept (KER-065), is being developed for the treatment of neuromuscular diseases.

Financial trend for Keros Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2024-12-31) to $243.86 million (2025-12-31); net income (loss) went from -$104.68 million (2022-12-31) to $87.01 million (2025-12-31), a change of +183.1%; total assets went from $306.78 million (2022-12-31) to $338.02 million (2025-12-31), a change of +10.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1664710, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Keros Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Keros Therapeutics, Inc. (CIK 1664710) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-03, and the most recent 10-K annual report was filed 2026-03-04. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 153 8-K or 6-K reports in Keros Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-03 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1664710 is on the EDGAR company page; the latest 10-K there is dated 2026-03-04 and the oldest filing in the recent index dates from 2016-04-29. Insider trades for Keros Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Maui land & pineapple company, inc. bullish and bearish analyst opinions

This section ties “Maui land & pineapple company, inc. bullish and bearish analyst opinions” to MAUI LAND & PINEAPPLE CO INC (ticker MLP), SEC Central Index Key 63330, an EDGAR registrant classified as “Real Estate” and organised in HI. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-01 by MAUI LAND & PINEAPPLE CO INC (CIK 63330) — source document:

Maui Land & Pineapple Company, Inc. is a Delaware corporation and the successor to a business organized in 1909 as a Hawai‘i corporation. The Company reincorporated from Hawai‘i to Delaware pursuant to a plan of conversion completed on July 18, 2022. Total authorized capital stock of the Company includes 48,000,000 shares, consisting of 43,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.0001 per share. Shares of the Company’s common stock are listed on the New York Stock Exchange (“NYSE”) under the ticker symbol “MLP.” Depending upon the context, the terms “Company,” “we,” “our,” and “us,” refer to either Maui Land & Pineapple Company, Inc. alone, or to Maui Land & Pineapple Company, Inc. and its subsidiaries collectively.

Financial trend for MAUI LAND & PINEAPPLE CO INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $20.96 million (2022-12-31) to $19.46 million (2025-12-31), a change of -7.2%; net income (loss) went from $1.79 million (2022-12-31) to -$10.58 million (2025-12-31), a change of -692.0%; total assets went from $42.41 million (2022-12-31) to $47.97 million (2025-12-31), a change of +13.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 63330, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures MAUI LAND & PINEAPPLE CO INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MAUI LAND & PINEAPPLE CO INC (CIK 63330) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-04-01. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 207 8-K or 6-K reports in MAUI LAND & PINEAPPLE CO INC’s recent EDGAR index, the 4 listed here run from 2026-05-27 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 63330 is on the EDGAR company page; the latest 10-K there is dated 2026-04-01 and the oldest filing in the recent index dates from 2002-01-14. Insider trades for MAUI LAND & PINEAPPLE CO INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mckinley acquisition corporation bullish and bearish analyst opinions

This section ties “Mckinley acquisition corporation bullish and bearish analyst opinions” to McKinley Acquisition Corp (ticker MKLY, MKLYR, MKLYU), SEC Central Index Key 2067592, an EDGAR registrant classified as “Services-Prepackaged Software” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a S-4/A dated 2026-10-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-27 by McKinley Acquisition Corp (CIK 2067592) — source document:

We are a newly formed blank check company, incorporated on March 27, 2025, as an exempted company under the laws of the Cayman Islands. Our purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more operating businesses (which we refer to throughout this report as our “initial business combination”). We have not identified any specific business combination target, and neither we nor anyone on our behalf has engaged in any substantive discussions, directly or indirectly, with any potential target. While our search will not be limited to a particular industry, geography, or stage of corporate development, we intend to focus on identifying and acquiring one or more businesses with a total enterprise value between $500 million and $2 billion that are well-positioned for long-term growth and value creation.

Financial trend for McKinley Acquisition Corp from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $602,427 (2025-09-30) to $899,136 (2026-06-30), a change of +49.3%; total assets went from $175.51 million (2025-09-30) to $179.34 million (2026-06-30), a change of +2.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2067592, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures McKinley Acquisition Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on McKinley Acquisition Corp (CIK 2067592) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-02-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for McKinley Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 10 such filings (424B4, 425, S-1, S-1/A, S-4) appear in its recent index, the newest dated 2026-10-05.

Current reports. Of the 4 8-K or 6-K reports in McKinley Acquisition Corp’s recent EDGAR index, the 4 listed here run from 2025-08-15 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2067592 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2025-05-09. Insider trades for McKinley Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Metrocity bankshares, inc. bullish and bearish analyst opinions

This section ties “Metrocity bankshares, inc. bullish and bearish analyst opinions” to MetroCity Bankshares, Inc. (ticker MCBS), SEC Central Index Key 1747068, an EDGAR registrant classified as “State Commercial Banks” and organised in GA. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-16 by MetroCity Bankshares, Inc. (CIK 1747068) — source document:

MetroCity Bankshares, Inc. (the “Company”), a bank holding company incorporated in 2014 and headquartered in the Atlanta metropolitan area. We primarily operate through our wholly-owned banking subsidiary, Metro City Bank, a Georgia state-chartered commercial bank that was founded in 2006 (the “Bank”). We currently operate 29 full-service branch locations in multi-ethnic communities in Alabama, California, Florida, Georgia, New York, New Jersey, Texas and Virginia. As of December 31, 2025, we had total assets of $4.77 billion, total loans held for investment of $4.08 billion, total deposits of $3.65 billion and total shareholders’ equity of $544.2 million. We are a full-service commercial bank focused on delivering personalized service in an efficient and reliable manner to the small-to medium-sized businesses and individuals in our markets, including many customers in diverse and multi-ethnic communities in growing metropolitan markets in the Eastern U.S., Texas and California.

Financial trend for MetroCity Bankshares, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $62.60 million (2022-12-31) to $68.53 million (2025-12-31), a change of +9.5%; total assets went from $3.43 billion (2022-12-31) to $4.77 billion (2025-12-31), a change of +39.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1747068, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures MetroCity Bankshares, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MetroCity Bankshares, Inc. (CIK 1747068) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-23, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 83 8-K or 6-K reports in MetroCity Bankshares, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-24 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1747068 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2018-08-17. Insider trades for MetroCity Bankshares, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Nervgen pharma corp. common stock bullish and bearish analyst opinions

This section ties “Nervgen pharma corp. common stock bullish and bearish analyst opinions” to NERVGEN PHARMA CORP. (ticker NGEN), SEC Central Index Key 1751912, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K/A dated 2026-10-16. Nothing here is a recommendation to trade the security.

Financial trend for NERVGEN PHARMA CORP. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) went from -24,250,049 CAD (2024-12-31) to -44,117,305 CAD (2025-12-31), a change of -81.9%; total assets went from 19,486,223 CAD (2024-12-31) to 23,209,641 CAD (2025-12-31), a change of +19.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1751912, tags Assets, ProfitLoss; 2 periods shown, dashes mark figures NERVGEN PHARMA CORP. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on NERVGEN PHARMA CORP. (CIK 1751912) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 40-F annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 14 8-K or 6-K reports in NERVGEN PHARMA CORP.’s recent EDGAR index, the 4 listed here run from 2026-07-02 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 41 recent EDGAR filings, NERVGEN PHARMA CORP. most often filed 6-K (14), D (7), SUPPL (4), EFFECT (2). A selection from 2026-05-26 to 2026-10-16:

The full record for CIK 1751912 is on the EDGAR company page; the latest 40-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 2018-09-20. Insider trades for NERVGEN PHARMA CORP. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Oatly group ab bullish and bearish analyst opinions

This section ties “Oatly group ab bullish and bearish analyst opinions” to Oatly Group AB (ticker OTLY), SEC Central Index Key 1843586, an EDGAR registrant classified as “Food and Kindred Products” and organised in Sweden, formerly known as Havre Global AB. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-24. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-13 by Oatly Group AB (CIK 1843586) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 65 A. Operating Results 65 B. Liquidity and Capital Resources 77 C. Research and Development, Patents and Licenses, etc. 80 D. Trend Information 80 E. Critical Accounting Estimates 80 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 80 A. Directors and Senior Management 80 B. Compensation 83 C. Board Practices 88 D. Employees 91 E. Share Ownership 91 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 91 A. Major Shareholders 91 B. Related Party Transactions 94 C. Interests of Experts and Counsel 96 ITEM 8. FINANCIAL INFORMATION 97 A. Consolidated Statements and Other Financial Information 97 B. Significant Changes 97 ITEM 9. THE OFFER AND LISTING 97 A. Offer and Listing Details 97 B. Plan of Distribution 97 C. Markets 97 D. Selling Shareholders 98 E. Dilution 98 i F. Expenses of the Issue 98 ITEM 10.

Financial trend for Oatly Group AB from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $722.24 million (2022-12-31) to $862.46 million (2025-12-31), a change of +19.4%; net income (loss) went from -$392.57 million (2022-12-31) to -$153.12 million (2025-12-31), a change of +61.0%; total assets went from $1.23 billion (2022-12-31) to $787.20 million (2025-12-31), a change of -35.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1843586, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Oatly Group AB did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Oatly Group AB (CIK 1843586) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 84 8-K or 6-K reports in Oatly Group AB’s recent EDGAR index, the 4 listed here run from 2026-05-20 to 2026-09-24, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1843586 is on the EDGAR company page; the latest 20-F there is dated 2026-03-13 and the oldest filing in the recent index dates from 2021-02-12. Insider trades for Oatly Group AB appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Onkure therapeutics, inc. bullish and bearish analyst opinions

This section ties “Onkure therapeutics, inc. bullish and bearish analyst opinions” to OnKure Therapeutics, Inc. (ticker OKUR), SEC Central Index Key 1637715, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as Reneo Pharmaceuticals, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-12 by OnKure Therapeutics, Inc. (CIK 1637715) — source document:

OnKure Therapeutics, Inc. (“OnKure”, “we”, “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies. Using a structure-based drug design platform, we are committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to achieve optimal efficacy and tolerability by selectively targeting specific mutations shown to be key drivers of cancer and other diseases. By selectively sparing the wild-type enzyme and preferentially targeting the mutated form of the protein, which is oncogenic and drives disease processes in both cancer and vascular overgrowth syndromes, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from non-selective inhibition of the non-mutated (or wild-type) version of the protein.

Financial trend for OnKure Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2024-12-31 at $0; net income (loss) went from -$51.95 million (2022-12-31) to -$59.52 million (2025-12-31), a change of -14.6%; total assets went from $108.18 million (2022-12-31) to $62.12 million (2025-12-31), a change of -42.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1637715, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures OnKure Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on OnKure Therapeutics, Inc. (CIK 1637715) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-04, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 54 8-K or 6-K reports in OnKure Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1637715 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2018-01-08. Insider trades for OnKure Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Prairie lithium limited bullish and bearish analyst opinions

Read from its name, “Prairie lithium limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Prairie lithium limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Prairie lithium limited” appears in 23 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “prairie” (search terms considered: prairie, lithium).

In the 23 most relevant full-text hits returned for “Prairie lithium limited”, filings range from 2025-10-21 to 2026-08-13. The filers whose documents mention it most often are Stardust Power Inc. (SDST, SDSTW) (CIK 0001831979) (23 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 195+ entities whose registered name contains the word “prairie”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “prairie” 195, “lithium” 89. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “prairie” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Profusa, inc. common stock bullish and bearish analyst opinions

This section ties “Profusa, inc. common stock bullish and bearish analyst opinions” to Profusa, Inc. (ticker PFSA, NVACW), SEC Central Index Key 1859807, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE, formerly known as NorthView Acquisition Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-15. Nothing here is a recommendation to trade the security.

Financial trend for Profusa, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2024-12-31 at $100,000; net income (loss) went from $7.17 million (2022-12-31) to -$35.82 million (2025-12-31), a change of -599.8%; total assets went from $194.74 million (2022-12-31) to $3.77 million (2025-12-31), a change of -98.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1859807, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Profusa, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Profusa, Inc. (CIK 1859807) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-20, and the most recent 10-K annual report was filed 2026-04-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 73 8-K or 6-K reports in Profusa, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-21 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 322 recent EDGAR filings, Profusa, Inc. most often filed 8-K (73), CORRESP (33), UPLOAD (25), 4 (24). A selection from 2026-08-19 to 2026-09-04:

The full record for CIK 1859807 is on the EDGAR company page; the latest 10-K there is dated 2026-04-15 and the oldest filing in the recent index dates from 2021-06-17. Insider trades for Profusa, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pt champion pacific indonesia tbk bullish and bearish analyst opinions

The legal-form ending in “Pt champion pacific indonesia tbk” is the clue: “PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. A company of that kind reports in Indonesia, so the place to read its annual report and announcements is the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK — www.idx.co.id.

No SEC filer could be matched to “Pt champion pacific indonesia tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Pt champion pacific indonesia tbk”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “champion” (search terms considered: champion, pacific, indonesia).

Even the shorter phrase “Pt champion pacific” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (champion, pacific, indonesia) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “champion” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 139 entities whose registered name contains the word “champion”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “champion” 139, “pacific” 454, “indonesia” 36. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “champion” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET